Risklick Unveils Innovative AI Software to Transform Trials
Revolutionizing Clinical Trials with AI
Protocol AI accelerates clinical trial development and enhances patient access to medical devices. This innovative software, a product of Risklick, aims to transform the landscape of medical device trials through artificial intelligence.
The Need for Innovation in Trials
Bringing a medical device to market usually spans three to seven years, and clinical investigations are among the most extensive and costly phases. Each trial commences with a meticulously crafted protocol, the gateway to successful clinical investigation. The traditional process to develop this protocol often extends six months, during which minor mistakes can jeopardize the entire study.
Introducing Protocol AI
Risklick, originating from the University of Bern, has unveiled a revolutionary software called Protocol AI. This solution significantly cuts down both the timeline and expenses associated with clinical trials, ultimately facilitating patient access to groundbreaking treatments. According to Poorya Amini, Risklick's CEO, the platform has achieved a remarkable 50% reduction in the time spent crafting study documentation for medicinal products, with similar results anticipated for medical devices.
How Protocol AI Works
Protocol AI employs advanced Natural Language Processing (NLP) and Machine Learning (ML) technologies to scrutinize clinical data, existing publications, and regulatory frameworks. This capability enables the software to optimize study designs and foster evidence-based decision-making efficiently. By generating clinical trial protocols automatically in mere minutes using Large Language Models (LLM), Protocol AI positions experts with essential parameters needed in the continuously evolving medical device arena.
Boosting Success Rates in Trials
By simplifying the protocol development process, Protocol AI not only improves efficiency but also upholds quality standards essential for successful clinical trials. This software is anticipated to catalyze medical innovations, thus enhancing the quality of life for countless patients globally.
Partnerships Driving Progress
Risklick has partnered with notable players in the industry to facilitate this advancement in clinical trials. Collaborating with Debiopharm, a front-runner in biotechnology, and ISS AG, a Swiss company specializing in medical devices and digital medicine, underscores Risklick’s commitment to integrating innovation within the healthcare sector.
Contact Information
For more information, feel free to connect with:
Dr. Poorya Amini
CEO & Founder
Risklick AG
Spitalackerstrasse 26
CH-3013 Bern, Switzerland
Tel: +41 78 781 41 35
Frequently Asked Questions
What is Protocol AI?
Protocol AI is an AI-based software developed by Risklick designed to streamline and accelerate the clinical trial process for medical devices.
How does Protocol AI benefit clinical trials?
This software reduces development time and costs, ensuring a quicker pathway for patients to access innovative medical devices.
Who developed Protocol AI?
Protocol AI was created by Risklick, a spin-off from the University of Bern in Switzerland.
What technologies does Protocol AI employ?
Protocol AI utilizes Natural Language Processing (NLP) and Machine Learning (ML) technologies to enhance trial design and protocol generation.
Who are Risklick's partners?
Risklick collaborates with major firms such as Debiopharm and ISS AG to further its goal of improving clinical trials in the healthcare sector.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.
